The Evening versus Morning Polypill Utilization Study: The TEMPUS rationale and design

European Journal of Preventive Cardiology

Volumn 21, Issue 4, 2014, Pages 425-433

  Lafeber, Melvin ^a   Grobbee, Diederick E ^a   Bots, Michiel L ^a   Thom, Simon ^b   Webster, Ruth ^c   Rodgers, Anthony ^c   Visseren, Frank Lj ^a   Spiering, Wilko ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

Author keywords

Antiplatelet agents; blood pressure lowering agents; cardiovascular disease; cholesterol lowering agents; chronotherapy; combination therapy; polypill; prevention

Indexed keywords

ACETYLSALICYLIC ACID; HIGH DENSITY LIPOPROTEIN; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; DRUG COMBINATION; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TABLET;

ADULT; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BIOCHEMISTRY; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; EVENING DOSAGE; HUMAN; MAJOR CLINICAL STUDY; MORNING DOSAGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE WAVE; RISK FACTOR; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE FUNCTION; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHRONOTHERAPY; CLINICAL PROTOCOL; COMPARATIVE STUDY; COMPLICATION; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECTS; DYSLIPIDEMIAS; HYPERTENSION; METABOLISM; METHODOLOGY; NETHERLANDS; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TABLET; THROMBOCYTE; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTIHYPERTENSIVE AGENTS; ASPIRIN; BIOLOGICAL MARKERS; BLOOD PLATELETS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CLINICAL PROTOCOLS; CROSS-OVER STUDIES; DRUG CHRONOTHERAPY; DRUG COMBINATIONS; DYSLIPIDEMIAS; HUMANS; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; LISINOPRIL; NETHERLANDS; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; PROSPECTIVE STUDIES; RESEARCH DESIGN; SIMVASTATIN; TABLETS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84894228302     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/2047487313476961     Document Type: Article

References (38)

1. Callow AD. Cardiovascular disease 2005 - the global picture. Vascul Pharmacol. 2006 ; 45: 302-307
2. Rayner M, Allender S, Scarborough P. Cardiovascular disease in Europe. Eur J Cardiovasc Prev Rehabil. 2009 ; 16: S43 - S47
3. Group PC. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001 ; 358: 1033-1041
4. Collaboration AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 ; 324: 71-86
5. Group HPSC. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002 ; 360: 7-22
6. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000 ; 342: 145-153
7. Lafeber M, Spiering W, Singh K, et al. The cardiovascular polypill in high-risk patients. Eur J Cardiovasc Prev Rehabil 2011.
8. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011 ; 378: 1231-1243
9. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003 ; 326: 1419-1419
10. Secondary prevention of noncommuncicable diseases in low- and middle-income countries through community-based and health service interventions; report of WHO-Wellcome Trust Meeting of Experts, 1-3 August 2001. Hixton, Cambridge, UK. Geneva: WHO ; 2002 :
11. Yusuf S. Two decades of progress in preventing vascular disease. Lancet. 2002 ; 360: 2-3
12. Jones PJ, Schoeller DA. Evidence for diurnal periodicity in human cholesterol synthesis. J Lipid Res. 1990 ; 31: 667-673
13. Parker TS, McNamara DJ, Brown CD, et al. Plasma mevalonate as a measure of cholesterol synthesis in man. J Clin Invest. 1984 ; 74: 795-804
14. Saito Y, Yoshida S, Nakaya N, et al. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study. Arterioscler Thromb. 1991 ; 11: 816-826
15. Wallace A, Chinn D, Rubin G. Taking simvastatin in the morning compared with in the evening: randomised controlled trial. BMJ. 2003 ; 327: 788-788
16. Hermida RC, Ayala DE, Calvo C, et al. Aspirin administered at bedtime, but not on awakening, has an effect on ambulatory blood pressure in hypertensive patients. J Am Coll Cardiol. 2005 ; 46: 975-983
17. Snoep JD, Hovens MM, Pasha SM, et al. Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines. Hypertension. 2009 ; 54: 1136-1142
18. Hermida RC, Ayala DE, Mojon A, et al. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int. 2010 ; 27: 1629-1651
19. Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008 ; 336: 1114-1117
20. Simons PC, Algra A, van de Laak MF, et al. Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol. 1999 ; 15: 773-781
21. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999 ; 21: 1074-1090
22. Avanzini F, Palumbo G, Alli C, et al. Effects of low-dose aspirin on clinic and ambulatory blood pressure in treated hypertensive patients. Collaborative Group of the Primary Prevention Project (PPP) - Hypertension study. Am J Hypertens. 2000 ; 13: 611-616
23. Hermida RC, Ayala DE, Calvo C, et al. Administration time-dependent effects of aspirin on blood pressure in untreated hypertensive patients. Hypertension. 2003 ; 41: 1259-1267
24. Kriszbacher I, Ajtay Z, Koppan M, et al. Can the time of taking aspirin influence the frequency of cardiovascular events?. Am J Cardiol. 2005 ; 96: 608-610
25. Gallerani M, Manfredini R, Ricci L, et al. Chronobiological aspects of acute cerebrovascular diseases. Acta Neurol Scand. 1993 ; 87: 482-487
26. Mancia G, Ferrari A, Gregorini L, et al. Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res. 1983 ; 53: 96-104
27. Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood-pressure. Lancet. 1978 ; 1: 795-797
28. Morgan T, Anderson A, Jones E. The effect on 24 h blood pressure control of an angiotensin converting enzyme inhibitor (perindopril) administered in the morning or at night. J Hypertens. 1997 ; 15: 205-211
29. Middeke M, Kluglich M and Holzgreve H. Chronopharmacology of captopril plus hydrochlorothiazide in hypertension: morning versus evening dosing. Chronobiol Int 1991; 8.
30. Fuji J, Seki A. Compliance and compliance-improving strategies in hypertension: the Japanese experience. J Hypertens. 1985 ; 3: S19 - S22
31. Kruse W, Rampmaier J, Ullrich G, et al. Patterns of drug compliance with medications to be taken once and twice daily assessed by continuous electronic monitoring in primary care. J Clin Pharmacol Ther. 1994 ; 32: 452-457
32. Kruse W, Nikolause T, Rampmaier J, et al. Actual versus prescribed timing of lovastatin doses assessed by electronic compliance monitoring. Eur J Clin Pharamcol 1993; 45.
33. Mallion JM, Meilhac B, Tremel F, et al. Use of a microprocessor-equipped tablet box in monitoring compliance with antihypertensive treatment. J Cardiovasc Pharmacol. 1992 ; 19: S41 - S48
34. Mengden T, Binswanger B, Spuhler T, et al. The use of self-measured blood pressure determinations in assessing dynamics of drug compliance in a study with amlodipine once a day, morning versus evening. J Hypertens. 1993 ; 11: 1403-1411
35. Yusuf S, Pais P, Afzal R, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009 ; 373: 1341-1351
36. Malekzadeh F, Marshall T, Pourshams A, et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors. Int J Clin Pract 64: 1220-1227.
37. Rodgers A, Patel A, Berwanger O, et al. An international randomised placebo-controlled trial of a four-component combination pill ('polypill') in people with raised cardiovascular risk. PLoS One. 2011 ; 6: e19857 - e19857
38. Thom S, Field J, Poulter N, et al. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe. Eur J Prev Cardiol 2012 (Epub ahead of print). DOI: 10.1177/ 2047487312463278.